H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Aslan Pharmaceuticals to $17 from $20 and keeps a Buy rating on the shares following the Q1 results. The analyst continues to believe that 2023 could be a transformational year for the company.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ASLN:
- Is ASLN a Buy, Before Earnings?
- ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Aslan Pharmaceuticals announces anticipated milestones
- Aslan Pharmaceuticals expects cash to fund operations through 2Q24
- Aslan Pharmaceuticals reports Q1 EPS (5c) vs. (4c) last year